EN

ENZYCHEM LIFESCIENCES CORPORATION

Develops small molecule therapeutics for cancer, inflammation, and respiratory diseases.

183490 | KO

Overview

Corporate Details

ISIN(s):
KR7183490002
LEI:
Country:
South Korea
Address:
충청북도 제천시 바이오밸리로 59, 제천시

Description

Enzychem Lifesciences Corporation is a biopharmaceutical company that develops novel small molecule therapeutics. The company's research targets fundamental pathways in inflammation to address significant unmet medical needs for patients with cancer, inflammatory diseases, and severe respiratory conditions. Its leading drug candidate, EC-18 (Mosedipimod), is a first-in-class oral small molecule derived from Sika deer antler. The clinical pipeline for EC-18 includes indications such as chemoradiation-induced oral mucositis (CRIOM), chemotherapy-induced neutropenia (CIN), acute radiation syndrome (ARS), and non-alcoholic steatohepatitis (NASH). The company also develops and manufactures Active Pharmaceutical Ingredients (APIs).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-02-06 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 22.2 KB
2024-02-02 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean HTML 11.5 KB
2024-01-15 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 86.0 KB
2023-12-19 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 21.4 KB
2023-12-15 00:00
주주명부폐쇄기간또는기준일설정
Korean HTML 4.2 KB
2023-12-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 21.4 KB
2023-11-21 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 21.4 KB
2023-11-14 00:00
분기보고서 (2023.09)
Korean HTML 2.1 MB
2023-11-10 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 83.8 KB
2023-11-10 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 22.2 KB
2023-11-03 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 21.4 KB
2023-10-31 00:00
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 47.7 KB
2023-10-31 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 22.2 KB
2023-10-17 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 83.8 KB
2023-10-17 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 22.1 KB

Automate Your Workflow. Get a real-time feed of all ENZYCHEM LIFESCIENCES CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ENZYCHEM LIFESCIENCES CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ENZYCHEM LIFESCIENCES CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.